Top in women’s health: Future of mifepristone; Biden invests in women’s health research
Click Here to Manage Email Alerts
On March 26, the Supreme Court heard oral arguments regarding the accessibility, efficacy and safety of mifepristone, a drug commonly used for medication abortion.
Depending on the ruling, mifepristone may lose its FDA approval. Healio spoke with an expert about the potential consequences of removing or limiting access to the drug.
“I think mifepristone is incredibly important for women’s health care,” Kristyn M. Brandi, MD, MPH, FACOG, an OB/GYN physician and complex family planning subspecialist, told Healio. “Reproductive health care has few medications that we use regularly, and mifepristone is probably one of the medications I give patients the most often in my practice.”
It was the top story in women’s health last week.
In another top story, President Joe Biden signed an executive order to prioritize women’s health in the federal research portfolio and budget. This follows his State of the Union address, in which he urged Congress to allocate funds to new women’s health research.
Read these and more top stories in women’s health below:
Q&A: What happens if mifepristone loses FDA approval?
Since the Dobbs decision in June 2022, mifepristone has been heavily discussed within legal landscapes regarding its safety, efficacy and availability for women seeking medication abortion. Read more.
Biden signs executive order, announces actions to improve women’s health
On March 18, President Joe Biden signed an executive order and announced new actions to improve women’s health research and innovation in the United States, according to a White House press release. Read more.
Q&A: Preeclampsia follow-up program urges women to be proactive in CVD prevention
Preeclampsia significantly increases future risk for CVD; however, many women with preeclampsia fail to attend postpartum follow-up visits and, therefore, do not receive proper preventive care. Read more.
Non-hormone drugs can reduce menopausal hot flash frequency, severity
Fezolinetant and elinzanetant are both promising nonhormone therapies for managing vasomotor symptoms among postmenopausal women, with favorable safety profiles for up to 12 weeks, according to a systematic review published in Menopause. Read more.
Preterm birth rates vary across nativity, ethnicity and racial identities
Risks for preterm birth overall and by gestational age varied for women across all nativity, ethnicity and racial identities, according to a retrospective national cohort study published in JAMA Network Open. Read more.